文献速递真菌感染医院感染防控

危重症患者体外膜氧合期间静脉泊沙康唑的药代动力学与靶标达成

Pharmacokinetics and target attainment of intravenous posaconazole in critically ill patients during extracorporeal membrane oxygenation.
PubMed 文献 · J Antimicrob Chemother · 2021-01-01

该研究纳入6例接受体外膜氧合(ECMO)并静脉使用泊沙康唑的危重症患者,在早期和晚期两个采样日采集血样,采用非房室分析和群体药代动力学模型评估暴露与靶标达成。结果显示ECMO似乎不影响泊沙康唑暴露,预防靶标达成率>90%,但治疗靶标未达成,部分谷浓度低于治疗下限。

要点

  • ECMO似乎不影响泊沙康唑暴露,与血液病患者相当。
  • 预防靶标PTA>90%达成,但治疗靶标未达成。
  • 建议进行治疗药物监测,无需常规经验性剂量调整。

核心结论

  • ECMO似乎不影响泊沙康唑暴露,但部分谷浓度低于治疗下限,建议进行治疗药物监测。

研究设计与样本

  • 前瞻性药代动力学研究,纳入6例接受ECMO并静脉使用泊沙康唑的危重症患者,在早期(第2-3天)和晚期(第4-7天)两个采样日采集血样。

主要发现

  • 非房室分析中位(IQR)AUC0-24为34.3(28.3-37.7)mg·h/L,CL为8.7(8.0-10.6)L/h,Vd为389(314-740)L。
  • 所有实测谷浓度≥0.7 mg/L,其中11/16≥1 mg/L,分别对应血液系统预防和治疗侵袭性曲霉病的阈值。
  • 预防靶标PTA>90%达成,治疗靶标未达成。

关键数值与推荐

  • 预防侵袭性曲霉病的谷浓度阈值为≥0.7 mg/L,治疗阈值为≥1 mg/L。
  • 预防靶标PTA>90%达成,治疗靶标未达成。

临床怎么用

  • ECMO患者使用静脉泊沙康唑无需常规经验性剂量调整,但推荐进行治疗药物监测。

局限性

  • 样本量小(仅6例),结论需更大样本验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Posaconazole is an antifungal drug used for prophylaxis and treatment of invasive fungal infections. Severe influenza has been identified as a risk factor for invasive pulmonary aspergillosis in critically ill patients. In this population, extracorporeal membrane oxygenation (ECMO) is used as rescue therapy, although little is known about the pharmacokinetics (PK) of posaconazole during ECMO. OBJECTIVES: To determine the PK and target attainment of six patients treated with IV posaconazole under ECMO and to develop a population PK model that can be used to simulate the PTA. METHODS: Critically ill patients treated with posaconazole and ECMO were included in this study. Plasma samples were collected at several timepoints within one dosing interval on two occasions: an early (Day 2-3) and a late (Day 4-7) sampling day. Daily trough concentrations were measured. RESULTS: The median (IQR) AUC0-24, CL and Vd were 34.3 (28.3-37.7) mg·h/L, 8.7 (8.0-10.6) L/h and 389 (314-740) L, if calculated with non-compartmental analysis based on the observed concentrations. All measured trough concentrations were ≥0.7 mg/L and 11/16 were ≥1 mg/L, which are the haematological thresholds for prophylaxis and treatment of invasive aspergillosis, respectively. The targeted PTA (>90%) was attained for prophylaxis but not for treatment. CONCLUSIONS: ECMO does not appear to influence posaconazole exposure compared with haematology patients. However, some trough levels were below the lower limit for treatment. An a priori dose adjustment does not appear to be necessary but drug monitoring is recommended.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Van Daele R, Brüggemann RJ, Dreesen E, et al. Pharmacokinetics and target attainment of intravenous posaconazole in critically ill patients during extracorporeal membrane oxygenation. J Antimicrob Chemother. 2021. PMID: 33517360. doi:10.1093/jac/dkab012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。